Imagine a future where a computer algorithm decides whether you receive the medical treatment your doctor recommends. This is not science fiction; it’s a reality Medicare is testing right now. In a bold move, Medicare has launched a six-year pilot program called the Wasteful and Inappropriate Service Reduction Model (WISER), which uses artificial intelligence (AI) to review and potentially deny certain medical claims for patients enrolled in traditional Medicare. This experiment, starting in January 2026 across six states—Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington—aims to curb unnecessary spending but raises critical questions about patient care and access.
But here’s where it gets controversial: While the program targets 14 specific procedures and devices, like steroid injections for pain management and incontinence-control devices, it introduces a prior authorization requirement—a process traditionally absent in traditional Medicare. This means doctors must seek approval before providing these treatments, and AI will play a pivotal role in deciding whether a procedure is deemed 'wasteful' or 'inappropriate.'
And this is the part most people miss: The companies hired to manage these AI-driven decisions are paid a percentage of what Medicare would have spent on denied treatments. This financial incentive could lead to more aggressive denials, potentially putting patients at risk of being refused necessary care. As health economists who’ve studied Medicare and AI in healthcare, we believe this pilot could indeed save money, but it must be closely monitored to ensure it doesn’t harm patients.
The Stakes for Patients and Providers
Traditional Medicare, which covers about half of the 67 million Americans insured through the program, has long been praised for its straightforward access to care. Unlike Medicare Advantage plans, administered by private companies, traditional Medicare typically doesn’t require prior authorization. This pilot marks a significant shift, adding a bureaucratic layer that could delay or even block essential treatments.
For instance, if a patient needs arthroscopic treatment for an osteoarthritic knee, their doctor must first obtain approval from an AI system. If denied, the patient goes without treatment unless the provider successfully appeals—a process that adds stress and paperwork for both patients and doctors.
The Role of AI: A Double-Edged Sword
AI’s role in this pilot is both promising and concerning. On one hand, it could streamline decisions, automatically approving more cases and reducing wait times. On the other hand, it could enable companies to focus more intensely on cases flagged by AI, potentially increasing denials. Research suggests AI-aided prior authorization often leads to higher denial rates and greater reductions in healthcare use—a trend that could disproportionately affect vulnerable populations.
Here’s a thought-provoking question: If AI prioritizes cost-saving over individualized care, are we sacrificing the very essence of healthcare—compassion and personalized treatment? We invite you to share your thoughts in the comments.
What’s Next?
The pilot ends in December 2031, and if deemed successful, the Centers for Medicare & Medicaid Services could expand it to more states and procedures. While taxpayers stand to benefit from reduced Medicare costs, the trade-offs are significant. Tech companies may profit, but medical providers face increased paperwork and reduced payments. Patients, meanwhile, could lose access to necessary care if the AI system fails to distinguish between essential and unnecessary treatments.
The bottom line: This pilot is a high-stakes experiment that could reshape healthcare for millions. While cost-saving measures are crucial, especially given Medicare’s growing budget crisis, we must ask: Are we saving money at the expense of patient well-being? Let’s keep a close eye on this program and ensure that innovation doesn’t come at the cost of compassion.
